TABLE 1.
Baseline characteristics and follow-up duration of patients in the study group as a whole (overall) and considered separately according to sex and to anti-PLA2R below or above the median.
| Characteristic | Overall | Sex | Anti-PLA2R titer | ||
|---|---|---|---|---|---|
| Males | Females | Below median | Above median | ||
| (n = 204) | (n = 148) | (n = 56) | (n = 62) | (n = 63) | |
| Age (years) | 52.6 ± 15.5 | 52.6 ± 14.7 | 52.7 ± 17.6 | 54.3 ± 15.0 | 55.7 ± 13.1 |
| Male gender (n %) | 148 (72.5%) | 148 (100%) | 0 | 47 (75.8%) | 45 (71.4 %) |
| Clinical parameters | |||||
| BMI (kg/m2) | 26.9 ± 4.6 | 26.8 ± 3.8 | 27.4 ± 6.4 | 26.5 ± 4.1 | 27.2 ± 5.0 |
| Systolic blood pressure (mmHg) | 143.2 ± 17.5 | 135.2 ± 17.1 | 131.6 ± 18.4 | 135.0 ± 17.8 | 136.8 ± 16.9 |
| Diastolic blood pressure (mmHg) | 80.8 ± 9.8 | 82.4 ± 9.8 | 76.6 ± 8.6°°° | 80.0 ± 9.1 | 81.5 ± 9.2 |
| Reported duration of proteinuria (median, mo) | 24.9 (11.0–64.6) | 24.7 (10.9–68.6) | 25.4 (11.5–47.0) | 25.3 (10.6–83.0) | 18.4 (11.5–37.9) |
| (mean, mo) | 51.6 ± 67.7 | 52.6 ± 69.0 | 48.6 ± 64.7 | 61.9 ± 81.6 | 32.9 ± 40.4 |
| Laboratory parameters | |||||
| Serum creatinine (mg/dl) | 1.4 ± 0.7 | 1.5 ± 0.8 | 1.1 ± 0.4° | 1.3 ± 0.5 | 1.5 ± 0.7 |
| Serum albumin (g/dl) | 2.4 ± 0.7 | 2.4 ± 0.8 | 2.4 ± 0.6 | 2.2 ± 0.6 | 2.0 ± 0.5 |
| Serum proteins (g/dl) | 4.8 ± 0.9 | 4.8 ± 1.0 | 4.8 ± 0.7 | 4.6 ± 0.7 | 4.4 ± 0.7 |
| Total cholesterol (mg/dl) | 266.0 ± 82.6 | 262.9 ± 82.8 | 274.2 ± 82.1 | 274.7 ± 75.5 | 277.2 ± 88.4 |
| HDL cholesterol (mg/dl) | 56.3 ± 19.1 | 51.8 ± 15.2 | 68.2 ± 23.1°°° | 56.0 ± 17.0 | 54.5 ± 18.4 |
| Triglycerides (mg/dl) | 179.6 ± 104.7 | 191.9 ± 113.1 | 147.3 ± 69.5°° | 166.3 ± 90.9 | 199.6 ± 124.7 |
| Proteinuria (g/24 h) | 8.3 (4.9–12.0) | 9.2 (5.9–13.0) | 5.8 (3.8–8.4)°°° | 8.6 (5.6–11.8) | 11.0 (7.7–13.6)* |
| Iohexol-measured GFR (ml/min/1.73 m2) | 62.3 ± 25.8 | 63.6 ± 26.2 | 59.2 ± 24.9° | 60.2 ± 23.3 | 55.5 ± 19.0 |
| Anti-PLA2R1 | |||||
| Titer (RU/ml) | 217.3 ± 489.8 | 159.1 ± 178.1 | 387.4 ± 908.5 | 69.3 ± 35.9 | 445.7 ± 691.5 *** |
| Detectable/undetectable/unavailable | 125/24/55 | 92/19/37 | 33/5/18 | - | - |
| Follow-up (mo) | 24.8 (12.0–36.0) | 24.0 (12.3–36.0) | 17.4 (10.1–36.0) | 22.0 (12.0–36.0) | 24.1 (15.0–37.6) |
Variables are expressed as mean ± SD, or as median and IQR, or both. Categorical variables are expressed as a number (percentage).
°p < 0.05, °°p < 0.01, °°°p < 0.001 versus males; *p < 0.05, ***p < 0.001 V S, below anti-PLA2R median (unpaired t-test or Wilcoxon rank-sum test, as appropriate).